| Catalog No. | Size | Price (USD) |
| 101569-T08-50 | 50 µL | $147.96 |
| 101569-T08-100 | 100 µL | $251.64 |
| 101569-T08-200 | 200 µL | $355.32 |
General Information
| Product name | Anti-ARID3A Antibody, Rabbit Polyclonal |
| Validated applications | IHC-P (FAQ Protocol) |
| Species reactivity | Reacts with: Human |
| Specificity | Human ARID3A |
| Immunogen | A synthetic peptide corresponding to the center region of the Human ARID3A |
| Preparation | Produced in rabbits immunized with a synthetic peptide corresponding to the center region of the Human ARID3A, and purified by antigen affinity chromatography. |
| Source | Polyclonal Rabbit IgG |
| Purification | Protein A & Antigen Affinity |
| Formulation | 0.2 μm filtered solution in PBS |
| Conjugate | Unconjugated |
| Form | Liquid |
| Shipping | This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Storage | This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles. |
Synonyms: Anti-BRIGHT Antibody; Anti-DRIL1 Antibody; Anti-DRIL3 Antibody; Anti-DRX Antibody; Anti-E2FBP1 Antibody
Image / Experimental Information
| Image 1 Description | Immunochemical staining of human ARID1A in human ovarian cancer with rabbit polyclonal antibody (1:1000, formalin-fixed paraffin embedded sections). |
| Image 1 Alt Text | Human ARID3A Immunohistochemistry(IHC) 17290 |
| Image 1 URL | Source image |
| Image 2 Description | Immunochemical staining of human ARID1A in human ovarian cancer with rabbit polyclonal antibody (1:1000, formalin-fixed paraffin embedded sections). |
| Image 2 Alt Text | Human ARID3A Immunohistochemistry(IHC) 17291 |
| Image 2 URL | Source image |
Background Information
| Description | ARID3A/DRIL1/Bright is a family member of the AT rich interaction domain (ARID) DNA-binding proteins that are involved in diverse biological processes, and p53 activates ARID3A transcription, and ARID3A overexpression induces G1 arrest. Both cooperative and interdependent roles for ARID3A and p53 in the transcriptional activation of p21(WAF1) in response to DNA damage. Conventional Arid3a knockout embryos suffer restricted intrauterine growth with severe defects in placental structural organization. ARID3A in mammalian placental development through regulation of both intrinsic and extrinsic developmental programs. AT-rich interactive domain 3A (ARID3A) is a member of the ARID family of DNA-binding proteins. Previous reports have shown that ARID3A controls cell growth in a p53-dependent manner. Recently, it has been reported that expression of the ARID3A protein was markedly increased in colon cancer tissue compared with matched normal colonic mucosa. ARID3A plays an important role in E2F-mediated transcriptional activation and cell growth. Bright/ARID3A is a nuclear matrix-associated transcription factor that stimulates immunoglobulin heavy chain (IgH) expression and Cyclin E1/E2F-dependent cell cycle progression. Bright positively activates IgH transcriptional initiation by binding to ATC-rich P sites within nuclear matrix attachment regions (MARs) flanking the IgH intronic enhancer (Emu). |
-HD10MA2825-1ug-ovarian-cancer-IHC-P.png){kind=link}
-HD10MA2825-1ug-colon-carcinoma-IHC-P.png){kind=link}